Vol. 65 No. 5 (2019), ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH

Vol. 65 No. 5 (2019)

INNOVATIVE APPROACHES TO THE DIAGNOSIS OF SKIN MELANOMA: DEVELOPMENT VECTORS (INTERMEDIATE RESULTS)

ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH

https://doi.org/10.37469/0507-3758-2019-65-5-744-748

Published 01.05.2019

Yelena Antonova⁺⁻
Irina Baldueva⁺⁻
Aleksandr Solovev⁺⁻
A. Baranov⁺⁻
A. Khambikova⁺⁻
Tatyana Nekhaeva⁺⁻
L. Wayn⁺⁻
A. Zamir⁺⁻
I. Sinai⁺⁻

Yelena Antonova

Ulyanovsk State Pedagogical University

Irina Baldueva

N.N. Petrov National Medical Research Center of Oncology

Aleksandr Solovev

Ulyanovsk State Pedagogical University

A. Baranov

Ulyanovsk State Pedagogical University

A. Khambikova

Ulyanovsk State Pedagogical University

Tatyana Nekhaeva

N.N. Petrov National Medical Research Center of Oncology

L. Wayn

Emerald Medical Applications Ltd

A. Zamir

Emerald Medical Applications Ltd

I. Sinai

Emerald Medical Applications Ltd

##article.numberofdownloads## 54

##article.numberofviews## 130

PDF (Русский)

Keywords

SNP-ПОЛИМОРФИЗМЫ
MELANOMA
HEREDITARY
SCREENING
SNP
FREQUENCIES

How to Cite

Antonova, Y., Baldueva, I., Solovev, A., Baranov, A., Khambikova, A., Nekhaeva, T., Wayn, L., Zamir, A., & Sinai, I. (2019). INNOVATIVE APPROACHES TO THE DIAGNOSIS OF SKIN MELANOMA: DEVELOPMENT VECTORS (INTERMEDIATE RESULTS). Voprosy Onkologii, 65(5), 744–748. https://doi.org/10.37469/0507-3758-2019-65-5-744-748

Abstract

This article represents intermediate results of the research of the international project on the direction of complex diagnostics of skin melanoma. A preliminary screening of patients was carried out, which included the analysis of molecular markers of genomic DNA causing the development of susceptibility to the development of melanoma. In this paper, 7 gene polymorphisms of CDKN2A (cyclin-dependent kinase inhibitor 2A), MC1R (melanocortin 1 receptor) and MITF (microphthalmia transcription factor) are considered. In total, 122 patients were studied.

https://doi.org/10.37469/0507-3758-2019-65-5-744-748

##article.numberofdownloads## 54

##article.numberofviews## 130

PDF (Русский)

References

Мазуренко Н.Н. Генетические особенности и маркеры меланомы кожи // Успехи молекулярной онкологии. - 2014. - № 2. - С. 36-43.

Kumar S., Stecher G., Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets // Molecular Biology and Evolution. - 2016. - Vol. 33. - P. 1870-1874.

Новик А.В. Меланома кожи: новые подходы // Практическая онкология. - 2011. - Т. 2. - № 1. - С. 36-42.

Bohm M., Jagirdar K., Sturm R.A. et al. Lack of protection from development of multiple melanomas by an injected melanocortin analogue in a combined high-risk MC1R/ CDKN2A genotype patient // Journal of European Academy of Dermatology and Venereology. - 2016. - Vol. 30, Is. 10. - P. 65-67.

Botezatu I.V., Nechaeva I.O., Stroganova A.M. et al. Optimization of melting analysis with Taqman probes for de tection of KRAS, NRAS and BRAF mutations // Analytical Biochemistry. - 2015. - Vol. 491. - P. 75-83.

Davies M.A., Samuels Y Analysis of the genome to personalize therapy for melanoma // Oncogene. - 2010. - Vol. 29 (41). - P. 5545-5555.

Delaunay J., Martin L., de Paillerets B.D. et al. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Lowto Moderate Incidence. The Rule of 2 vs the Rule of 3 // JAMA Dermatology. - 2017. - Vol. 153 (11). - P. 1122-1129.

Fargnoli M.C., Gandini S., Peris K. et al. MC1R variants increase melanoma risk in families with CDKN2A mutations: A meta-analysis // European Journal of Cancer. - 2010. - Vol. 46. - P. 1413-1420.

Harlanda M., Goldsteinb A.M., Kukalizcha K. et al. A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL) // European Journal of Cancer. - 2008. - Vol. 44 (9). - P. 1269-1274.

Hayward N.K., Wilmott J.S., Waddell N. et al. Whole-ge-nome landscapes of major melanoma subtypes // Nature. - 2017. - Vol. 545 (7653). - P. 175-180.

Helgadottir H., Tuominen R., Olsson H. et al. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status // Journal of American Academy of Dermatology. - 2017. - Vol. 77 (5). - P. 893-901.

Helgadottir H., Hoiom V., Tuominen R. et al. Germline CD-KN2A Mutation Status and Survival in Familial Melanoma Cases // Journal of the National Cancer Institute. - 2016. - Vol. 108 (11). - DOI: 10.1093/jnci/djw135

Leachman S.A., Olivia M. Lucero O.M. et al. Identification, genetic testing, and management of hereditary melanoma // Cancer Metastasis Rev. - 2017. - Vol. 36. - P. 77-90.

Levin T, Mæhle L. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway // Familial Cancer. - 2017. - Vol. 16. - P. 257-265.

Lynch H.T., Shaw T.G. Familial atypical multiple mole melanoma (FAMMM) syndrome: history, genetics, and heterogeneity // Familial Cancer. - 2016. - Vol. 15 (3). - P. 487-491.

Mangas C., Potrony M., Mainetti C. et al. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF // British Journal of Dermatology. - 2016. - Vol. 175 (5). - P. 1030-1037.

Melamed R.D., Aydin I.T., Rajan G.S. et al. Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma // The Journal of Investigative Dermatology. - 2017. - Vol. 137 (4). - P. 905-909.

Soura E., Eliades P.J., Shannon K. et al. Hereditary melanoma: Update on syndromes and management. Emerging melanoma cancer complexes and genetic counseling // Journal of American Academy of Dermatology. - 2016. - Vol. 74. - P. 411-420.

Taylor N.J., Mitra N., Goldstein A.M. et al. Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families // The Journal of Investigative Dermatology. - 2017. - Vol. 137 (12). - P. 2606-2612.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Yekaterina Anokhina, V. Rubinchik, Yekaterina Yaremenko, Gulfiya Teletaeva, Dilorom Latipova, Anna Semenova, Tatyana Semiglazova, Irina Baldueva, Svetlana Protsenko, Aleksey Novik, A. Oganesyan, IPILIMUMAB IN PATIENTS WITH DISSEMINATED MELANOMA: THE N.N. PETROV NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY EXPANDED ACCESS PROGRAM EXPERIENCE , Voprosy onkologii : Vol. 64 No. 3 (2018)
Yelizaveta Prosekina, Anna Danilova, Tatyana Nekhaeva, Irina Baldueva, THE CREATING OF THREE-DIMENSIONAL CELLULAR MODELS TO SOLVE THEORETICAL AND PRACTICAL PROBLEMS OF MODERN ONCOLOGY , Voprosy onkologii : Vol. 65 No. 5 (2019)
Irina Baldueva, N. Avdokina, Aleksey Belyaev, Aleksandr Shcherbakov, Tatyana Semiglazova, Yekaterina Anokhina, Yuriy Komarov, Dilorom Latipova, Gulfiya Teletaeva, Anna Semenova, Olga Galiullina, Natalya Yemelyanova, Nino Pipia, Mark Gelfond, Svetlana Protsenko, Anna Danilova, Tatyana Nekhaeva, Aleksey Novik, Z. Kotova, PERSPECTIVES IN ACTIVE SPECIFIC IMMUNOTHERAPY WITH AUTOLOGOUS IMMATURE DENDRITIC CELLS COMBINED WITH PHOTODYNAMIC THERAPY AND CYCLOPHOSPHAMIDE IN PATIENTS WITH DISSEMINATED MELANOMA RESISTANT TO STANDARD THERAPY , Voprosy onkologii : Vol. 63 No. 2 (2017)
Nino Pipia, Irina Baldueva, Anna Danilova, Natalya Avdonkina, Aleksey Novik, Tatyana Nekhaeva, Georgiy Gafton, Natalya Yemelyanova, IMMUNOSUPPRESSIVE POTENTIAL OF PERIPHERAL REGULATORY T-LYMPHOCYTES IN THE PROCESS OF TUMOR PROGRESSION IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMAS , Voprosy onkologii : Vol. 64 No. 3 (2018)
Aleksey Belyaev, Irina Baldueva, Georgiy Prokhorov, Denis Prokhorov, Natalya Yemelyanova, IMMUNOLOGICAL CHANGES IN PATIENTS WITH MALIGNANT TUMORS AFTER CRYOGENIC AND ULTRASONIC ABLATION OF A TUMOR , Voprosy onkologii : Vol. 63 No. 1 (2017)
Natalya Avdonkina, Anna Danilova, Tatyana Nekhaeva, Irina Baldueva, MODERN IDEAS ABOUT CLONAL EVOLUTION OF SARCOMAS , Voprosy onkologii : Vol. 65 No. 6 (2019)

<< < 1 2